Cost analysis of Raltegravir versus Atazanavir/r or Darunavir/r for treatment-naive adults with HIV-1 infection in the United States [Meeting abstract PIN19]

Davis, A. E., Brogan, A., & Goodwin, BB. (2016). Cost analysis of Raltegravir versus Atazanavir/r or Darunavir/r for treatment-naive adults with HIV-1 infection in the United States [Meeting abstract PIN19]. Value in Health, 19(3), A214-A215. https://doi.org/10.1016/j.jval.2016.03.1207

Abstract

RAL has the lowest per-person cost compared with two other common first-line regimens, DRV/r and ATV/r, each used in combination with TDF/FTC, for treatment-naive adults with HIV-1 infection in the US. These results were found to be robust in sensitivity and scenario analyses. This economic evidence further complements the known clinical benefits of RAL as reported in the ACTG 5257 clinical trial.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Development of a novel shared decision making aid for primary immunodeficiency diseases
Article

Community overdose surveillance
Article

Epigenetic biomarkers for smoking cessation